Dipyridamole injection
Function and Efficacy
It has anti-thrombotic effect. Dipyridamole inhibits platelet aggregation, and high concentrations (50μg/ml) can inhibit platelet release. The mechanism of action may be (1) inhibiting platelet uptake of adenosine, which is a platelet reaction inhibitor; (2) inhibiting phosphodiesterase, increasing cyclic adenosine monophosphate (cAMP) in platelets; (3) inhibiting the formation of thromboxane A2 (TXA2), a strong agonist of TXA2 platelet activity; (4) enhancing endogenous PGI2. Dipyridamole has a vasodilatory effect. Dogs given 0.5-4.0 mg/kg of dipyridamole via the duodenum produce dose-related decreases in systemic and coronary vascular resistance, lower systemic blood pressure, and increased coronary blood flow. It takes effect 24 minutes after administration and lasts for about 3 hours. The same hemodynamic effects are observed in humans. However, acute intravenous administration can reduce local myocardial perfusion in the distal end of the stenotic coronary artery. In 111-week oral studies in mice and 128-142-week oral studies in rats, 8, 25, and 75 mg/kg (1, 3.1, and 9.4 times the maximum recommended daily dose for humans) of dipyridamole did not produce significant carcinogenic effects. The results of the mutagenicity test were negative. In rat reproduction studies, 60 times the maximum recommended daily dose of dipyridamole was used, and no evidence of reproductive damage was shown. However, at 115 times the maximum recommended daily dose for humans, the number of corpora lutea was significantly reduced, and live embryo implantation was reduced. Studies in mice, rats, and rabbits showed no evidence that dipyridamole harmed the fetus. The oral LD50 for mice is 2150 mg/kg; the single oral lethal dose is 6000 mg/kg in rats and 350 mg/kg in dogs.
Ingredients
The chemical name of this product is: 2,2′,2′′,2′′′[(4,8-dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)bis(nitrogen)-tetraethanol.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| DipyridamoleIngredients |
It has anti-thrombotic effect. Dipyridamole inhibits platelet aggregation, and high concentrations (50μg/ml) can inhibit platelet release. The mechanism of action may be: ⑴ Inhibit platelet uptake of adenosine, which is a platelet reaction inhibitor; ⑵ Inhibit phosphodiesterase, which increases cyclic adenosine monophosphate (cAMP) in platelets; ⑶ Inhibit the formation of thromboxane A2 (TXA2), which is a strong agonist of platelet activity; ⑷ Enhance endogenous PGI2. Dipyridamole has a vasodilatory effect. Dogs given 0.5-4.0 mg/kg of dipyridamole via the duodenum produce dose-related decreases in systemic and coronary vascular resistance, lower systemic blood pressure, and increased coronary blood flow. It takes effect 24 minutes after administration and lasts for about 3 hours. The same hemodynamic effects are observed in humans. However, acute intravenous administration can reduce local myocardial perfusion in the distal end of the stenotic coronary artery. More |
58-32-2 | 35 |
Appearance
This product is a yellow clear liquid.
Indication
A trial of drugs to diagnose myocardial ischemia.
Usage and Dosage
0.142 mg/(kg·min), intravenous drip for 4 minutes.
Adverse Reactions
Common adverse reactions include dizziness, headache, vomiting, diarrhea, flushing, rash and itching, and rarely angina pectoris and liver dysfunction. Persistent or intolerable adverse reactions are rare and can be eliminated after stopping the drug.
Precautions
It is contraindicated in patients who are allergic to dipyridamole.
Special Population Medication
Precautions for children: The safety and efficacy of the drug for children under 12 years old have not been determined. Precautions for pregnancy and lactation: No appropriate controlled studies have been conducted in pregnant women, and it should only be used in pregnant women when necessary. Dipyridamole is excreted in human breast milk, so it should be used with caution in lactating women. Precautions for the elderly: No such experiment has been conducted and there are no reliable references.
Drug Interactions
⑴ It has a synergistic effect with aspirin. ⑵ When this product is used together with dicoumarol anticoagulants, bleeding does not increase or worsen.
Storage
Keep away from light and store in a sealed container.
Packaging Specification
2ml:10mg
Validity Period
24 months
Manufacturer
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
-
Founded in:
2001-06-22 -
Address:
No. 118, Huagong Road, Dongtou District, Wenzhou -
Tax NO.:
913303007303249630 -
Registered Funds:
327.30432 million yuan -
Website:
-
Email: